- Home
- IMUX vs PDEX Comparison
IMUX vs PDEX Comparison
Compare IMUX & PDEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- PDEX
- Stock Information
- Founded
- IMUX 2016
- PDEX 1978
- Country
- IMUX United States
- PDEX United States
- Employees
- IMUX N/A
- PDEX N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- PDEX Medical/Dental Instruments
- Sector
- IMUX Health Care
- PDEX Health Care
- Exchange
- IMUX Nasdaq
- PDEX Nasdaq
- Market Cap
- IMUX 92.2M
- PDEX 105.5M
- IPO Year
- IMUX N/A
- PDEX N/A
- Fundamental
- Price
- IMUX $0.72
- PDEX $31.25
- Analyst Decision
- IMUX Strong Buy
- PDEX Strong Buy
- Analyst Count
- IMUX 5
- PDEX 1
- Target Price
- IMUX $7.00
- PDEX $56.00
- AVG Volume (30 Days)
- IMUX 1.4M
- PDEX 92.8K
- Earning Date
- IMUX 11-06-2025
- PDEX 10-30-2025
- Dividend Yield
- IMUX N/A
- PDEX N/A
- EPS Growth
- IMUX N/A
- PDEX 122.94
- EPS
- IMUX N/A
- PDEX 3.31
- Revenue
- IMUX N/A
- PDEX $70,231,000.00
- Revenue This Year
- IMUX N/A
- PDEX $7.22
- Revenue Next Year
- IMUX N/A
- PDEX N/A
- P/E Ratio
- IMUX N/A
- PDEX $9.34
- Revenue Growth
- IMUX N/A
- PDEX 23.65
- 52 Week Low
- IMUX $0.56
- PDEX $23.47
- 52 Week High
- IMUX $1.42
- PDEX $70.26
- Technical
- Relative Strength Index (RSI)
- IMUX 37.43
- PDEX 49.35
- Support Level
- IMUX $0.67
- PDEX $32.18
- Resistance Level
- IMUX $0.87
- PDEX $36.89
- Average True Range (ATR)
- IMUX 0.05
- PDEX 1.89
- MACD
- IMUX -0.01
- PDEX 0.73
- Stochastic Oscillator
- IMUX 21.92
- PDEX 52.56
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About PDEX Pro-Dex Inc.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.